Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
This article was originally published in The Tan Sheet
Executive Summary
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
You may also be interested in...
In Brief
FDA reverses on OTC PPI fracture risk
In Brief
C&D may cover costs by raising prices
PPI-Clopidogrel Shows Benefit, But Omeprazole Concern Remains - Study
An analysis shows a benefit from using proton pump inhibitors with clopidogrel compared with using the antiplatelet drug alone, but reinforces concerns that the PPI omeprazole diminishes the efficacy of the blood thinner